In the last two decades, lymphoma treatment has been enhanced with new therapeutic options, such as monoclonal antibodies, which have improved the prognosis of lymphoma patients. Despite the progress, the cure is not achieved in all patients and those who are not cured by standard treatments have poor prognosis. Recent discoveries of the role of immune system in recognizing and eliminating the malignant cells have led to the development of new immune-targeted treatment modalities, many today representing standard of care in the treatment of lymphoma. CAR T-cell therapyCAR T-cell therapy significantly changed the treatment landscape of patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma. Axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel have shown meaningful benefit in patients with relapse/refractory diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, and transformed follicular lymphoma who experienced disease relapse after HDCT and ASCT. CAR T-cell therapy CAR T-cell therapyhas proven benefits as well in patients with relapsed/refractory diffuse large B cell lymphoma when compared to the standard second-line HDCT with ASCT. NivolumabNivolumab and pembrolizumab, humanized PD-1 monoclonal antibodies were investigated as monotherapies or in combinations with brentuximab vedotin, chemotherapy, or ipilimumab. Both drugs have proven benefit in terms of response rates, complete responses, and progression free survival in the published trials compared to standard salvage protocols and even first-line treatments. Bispecific antibodies blinatumomab, mosunetuzumab, odronextamab, and others are studied in both aggressive and indolent relapse/refractory B-cell lymphomas. These drugs have proven benefit in patients previously treated with a median three lines of therapy, those with refractory, those who relapsed after ASCT, and even previously treated with CAR T.